Annual report pursuant to Section 13 and 15(d)

Balances and Transaction with Related Parties (Details Textual)

Balances and Transaction with Related Parties (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Balances and Transaction with Related Parties (Textual)    
Loan granted to related party $ 19  
Aggregate of remaining potential commitment $ 89  
Percentage of receive incubator fees equal to payroll expense 20.00%  
Total expenses   $ 28
Indemnification agreement, description BiomX Israel entered into indemnification agreement with the Incubator on December 13, 2017. According to the agreement, the aggregate amount of the indemnification shall not exceed an aggregate of NIS 2,295 thousand (approximately $664 thousand). In addition, the indemnification is limited only to matters in connection with the Company’s compliance with the IIA regulations and that such indemnification undertakings will not derogate from any other indemnification undertakings to which BiomX Israel is bound.  
Issuance of shares on loan to treasury stock 5,700  
Janssen Research & Development, LLC [Member]    
Balances and Transaction with Related Parties (Textual)    
Research collaboration agreement, description BiomX Israel is eligible to receive fees totaling $167 thousand in instalments of $50 thousand within 60 days of signing of the agreement, $17 thousand upon completion of data processing, and two instalments of $50 thousand each, upon delivery of Signature Phase I of the Final Study Report (both terms defined within the agreement). This agreement ended in 2020, 30 days after the parties completed the research program and BiomX Israel provided Janssen with a final study report. As of December 31, 2019, consideration of $117 thousand had been received. The remaining $50 thousand consideration was received in January 2020.